Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4089214
Max Phase: Preclinical
Molecular Formula: C17H21N3O4
Molecular Weight: 331.37
Molecule Type: Small molecule
Associated Items:
ID: ALA4089214
Max Phase: Preclinical
Molecular Formula: C17H21N3O4
Molecular Weight: 331.37
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: O=C(CCCCCONC(=O)Nc1ccc2ccccc2c1)NO
Standard InChI: InChI=1S/C17H21N3O4/c21-16(19-23)8-2-1-5-11-24-20-17(22)18-15-10-9-13-6-3-4-7-14(13)12-15/h3-4,6-7,9-10,12,23H,1-2,5,8,11H2,(H,19,21)(H2,18,20,22)
Standard InChI Key: QOJZBGSTKPJQLK-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 331.37 | Molecular Weight (Monoisotopic): 331.1532 | AlogP: 2.96 | #Rotatable Bonds: 8 |
Polar Surface Area: 99.69 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 4 |
#RO5 Violations: 0 | HBA (Lipinski): 7 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 8.63 | CX Basic pKa: | CX LogP: 2.32 | CX LogD: 2.30 |
Aromatic Rings: 2 | Heavy Atoms: 24 | QED Weighted: 0.34 | Np Likeness Score: -0.78 |
1. Stenzel K, Hamacher A, Hansen FK, Gertzen CGW, Senger J, Marquardt V, Marek L, Marek M, Romier C, Remke M, Jung M, Gohlke H, Kassack MU, Kurz T.. (2017) Alkoxyurea-Based Histone Deacetylase Inhibitors Increase Cisplatin Potency in Chemoresistant Cancer Cell Lines., 60 (13): [PMID:28581289] [10.1021/acs.jmedchem.6b01538] |
Source(1):